Bonista Teriparatide Injection


The safety of FORTEO in the treatment of osteoporosis in men and postmenopausal women was assessed in two randomized, double-blind, placebo-controlled trials of 1382 patients (21% men, 79% women) aged 28 to 86 years (mean 67 years). The median durations of the trials were 11 months for men and 19 months for women, with 691 patients exposed to FORTEO and 691 patients to placebo. All patients received 1000 mg of calcium plus at least 400 IU of vitamin D supplementation per day. The incidence of all cause mortality was 1% in the FORTEO group and 1% in the placebo group. The incidence of serious adverse events was 16% in FORTEO patients and 19% in placebo patients. Early discontinuation due to adverse events occurred in 7% of FORTEO patients and 6% of placebo patients. Table 1 lists adverse events from the two principal osteoporosis trials in men and postmenopausal women that occurred in ≥2% of FORTEO-treated and more frequently than placebo-treated patients.

Product Details:

Strength 750 mcg
Packaging Size 3ml
Packaging Type Pre-Filled Pen
Composition Teriparatide 750mcg
Manufactured By Sun Pharmaceutical Industries Ltd
Manufacturer Sun Pharma
Shelf Life 36 Months
Usage/Application To Treat Osteoporosis
Prescription/Non-Prescription Prescription
Country of Origin Made In India


There are no reviews yet.

Be the first to review “Bonista Teriparatide Injection”

Your email address will not be published. Required fields are marked *

Shopping Cart